AAD 2026: A New Wave of Eczema and Psoriasis Treatments — What Skincare Shoppers Should Know
The 2026 American Academy of Dermatology meeting surfaced an unusually large pipeline of new prescription options for eczema and psoriasis. Here is what changes for skincare shoppers — and what stays the same.
What was reported
Dermatology Times has been recapping late-breaking data from the 2026 American Academy of Dermatology Annual Meeting (held in Denver, March 27–31) through their May issue. The editor-in-chief's letter highlighted a striking volume of pipeline progress on inflammatory skin conditions — atopic dermatitis especially, plus psoriasis and chronic hand eczema — with several mechanisms that did not exist as treatment options a few years ago.
The new atopic dermatitis options pursue different molecular targets — IL-4 receptor alpha inhibitors (rademikibart, MG-K10), OX40-OX40L modulation (amlitelimab), and STAT6 degradation (KT-621) — and showed early skin-clearance activity at the meeting. Pediatric readouts supported nemolizumab and topical roflumilast. On psoriasis, several oral agents (icotrokinra, zasocitinib, envudeucitinib) reported activity approaching what biologics have delivered.
Why this matters for a skincare audience
Two reasons. First, the conditions in this pipeline — atopic dermatitis, eczema, chronic hand dermatitis, psoriasis — are not "skincare problems". They are inflammatory skin diseases, and they are the conditions most likely to be misdiagnosed as a barrier or sensitivity issue when someone is shopping for a calming serum.
Second, the existence of these prescription pipelines means dermatologists now have meaningful options for skin that does not get better on a careful OTC routine. The conventional wisdom that "you have to live with it" is increasingly out of date.
How to tell the difference (and when to escalate)
A useful rule of thumb: if your skin reacts only to specific products or environments and improves on a simplified routine, you are most likely dealing with barrier dysfunction or contact sensitivity. If your skin remains red, itchy, or flaring on a simplified routine — especially if itch is significant, or if the same area keeps recurring — that is the pattern dermatologists are looking for to consider eczematous or psoriatic skin.
The most useful thing OTC skincare can do for inflammatory skin is the boring foundational work: gentle cleansing, ceramide-replenishing moisturiser, fragrance avoidance, broad-spectrum SPF. That is the routine your dermatologist will recommend you stay on alongside any prescription treatment.
The takeaway
The AAD pipeline is encouraging for a population that has historically been told to suffer through it. Nothing here changes what good daily skincare looks like for inflammatory skin — that has always been gentle, hydrating, and barrier-supportive. What is changing is that you now have a real reason to bring chronic, treatment-resistant flares to a dermatologist instead of buying another "soothing" serum.